Navigation Links
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
Date:8/4/2009

SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced today that it has moved its drug discovery collaboration with ELARA Pharmaceuticals to a new level. ChemPartner will provide fully integrated services in the areas of DMPK, pharmacology and toxicology for ELARA's lead oncology programs. Members of the joint project team from both sides will work closely together to design and execute a drug screening cascade.

"This new relationship is a natural result of the high quality services provided by ChemPartner," commented Dr. Joe Lewis, CEO and a founder of ELARA Pharmaceuticals. "The discovery support from ChemPartner helped our Hypoxia Signaling inhibitor program to move from academic discovery stage to early proof of concept. This led to a successful spin off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Our new integrated relationship will enable ELARA to further leverage ChemPartner's strong R&D capabilities from discovery to early development phase. We anticipate a stronger strategic partnership down the road as our program progresses."

"We are very pleased to see that our services helped ELARA turn innovative research at a renowned academic institution into a venture funded drug discovery company," said Michael Hui, founder and CEO of ChemPartner. "Our partnership demonstrates the strength of ChemPartner's innovation driven and fully integrated R&D service platform"

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

About ELARA Pharmaceuticals

ELARA Pharmaceuticals is a spin-off of the European Molecular Biology Laboratory in Heidelberg, and was founded to translate basic research findings into novel cancer treatments.

The company is developing a portfolio of highly-potent orally-available inhibitors of the hypoxia signalling pathway. The lead compound shows an excellent in vivo profile and is expected to move into formal preclinical development this year.

Further information is available at http://www.elarapharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 25, 2017 , ... LABS, Inc. ... were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; ... LABS was only able to offer NAT screening for blood donors under an Investigational ...
(Date:4/25/2017)... Ca (PRWEB) , ... April 25, 2017 , ... As ... in the series will explore the laboratory testing for DIC in order to illuminate ... hypercoagulable disorder which can occur in hospitalized patients resulting in a high degree of ...
(Date:4/25/2017)... Los Gatos, California (PRWEB) , ... April 25, ... ... of business, Analytical Services and Metrology Partners.     , Covalent’s Analytical Services ... labs. Most samples can be measured within 24 hours of receipt. There are ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design of ... pleased to introduce it to top lab design architects from around the country at ... VP of Industrial Design and Engineering Greg Casey will be at the show, where ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):